Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD266 APC

Anti-Hu CD266 APC

Regulatory status

RUO

Antigen

CD266

Clone

ITEM-4

Format

APC

Reactivity

Mouse, Human

Application

FC (QC tested)

Excitation laser

red (633 nm)

Variant

0.1 mg

1A-755-C100

In stock

242.00 USD

Variant

0.1 mg

1A-755-C100

In stock

242.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG2b

Specificity

The mouse monoclonal antibody ITEM-4 recognizes an extracellular epitope of CD266 / TWEAK R, a TNFR superfamily receptor for CD255 / TWEAK, a TNF-like weak inducer of apoptosis.

Application

FC (QC tested)

Application details

Flow cytometry: Recommended dilution: 5-15 μg/ml. Extracellular and intracellular staining.

Reactivity

Mouse, Human

Immunogen

human CD266-transfected P815 cells

Concentration

0.1 mg/ml

Preparation

Purified antibody is conjugated with activated allophycocyanin (APC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

TWEAKR, FN14, TNFRSF12A

Antigen description

CD266 / TWEAK R (TNFRSF12A), also known as FN14 (fibroblast growth factor-inducible 14) is a receptor for CD255 / TWEAK, the TNF-like weak inducer of apoptosis. CD266 is expressed on endothelial cells, as well as on some cancer tissues, and plays a role in CD255-induced endothelial cell migration, proliferation, and angiogenesis. The CD255-CD266 interaction, or antibody-mediated triggering of CD266 is also able to induce apoptosis and necrosis in CD266-positive cells (including tumor cells), which might have therapeutic potential.

Entrez Gene ID 51330

UniProt ID Q9NP84

Anti-Hu CD266 APC antibody (clone ITEM-4) specificity verification by flow cytometry

Anti-Hu CD266 APC antibody (concentration in sample 15 μg/ml, red-filled histogram) binds specifically to CD266 in intracellulary stained CD266 transfected L5178Y cells (upper panel), but not to intracellulary stained non-transfected L5178Y cells (lower panel). Level of non-specific binding was assessed using Mouse IgG2b isotype control APC antibody (MOPC-21) under same conditions (concentration in sample 15 μg/ml, black-dashed histogram).

Product specific references:

Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med. 2011 Jan;2(1):103-108
PubMed

Sanz AB, Sanchez-Niño MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A: Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells. PLoS One. 2012;7(10):e47440.
PubMed

Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol. 2003 Jan 1;170(1):341-8.
PubMed

Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H: Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol. 2010 Aug 1;185(3):1593-605.
PubMed